Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytochrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    86 result(s) found for: Cytochrome. Displaying page 3 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2014-004554-34 Sponsor Protocol Number: 2014-004554-34 Start Date*: 2015-10-15
    Sponsor Name:Bispebjerg Hospital
    Full Title: An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam,...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003559-21 Sponsor Protocol Number: CDEB025A2212 Start Date*: 2012-02-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin
    Medical condition: Hepatitis C and how biomarkers affect the response to treatment of the disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005254-53 Sponsor Protocol Number: BKOS-03 Start Date*: 2012-05-14
    Sponsor Name:Menarini Ricerche S.p.A
    Full Title: A double-blind, randomised, placebo controlled, sequential ascending dose study, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intra-articular doses of fasi...
    Medical condition: Ostoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002361-36 Sponsor Protocol Number: ONCOSUR-2012-01 Start Date*: 2012-10-17
    Sponsor Name:ONCOSUR
    Full Title: Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer.
    Medical condition: Metastatic HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002226-76 Sponsor Protocol Number: 6.1 Start Date*: 2012-11-13
    Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology
    Full Title: High “on treatment” platelet reactivity in the Intensive Care Unit
    Medical condition: mixed medical intensive care unit patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002812-36 Sponsor Protocol Number: PTC743-NEU-003-FA Start Date*: 2021-02-18
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA)
    Medical condition: Friedreich Ataxia (FA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004632-69 Sponsor Protocol Number: P060309 Start Date*: 2006-12-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Polymorphismes du gène codant pour le cytochrome 2C19 et réponse au clopidogrel chez le sujet sain
    Medical condition: volontaire sain
    Disease: Version SOC Term Classification Code Term Level
    8.1 10043414 Therapeutic response decreased PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020305-32 Sponsor Protocol Number: CRAD001CIT27T Start Date*: 2010-08-06
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as...
    Medical condition: patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003575-11 Sponsor Protocol Number: VitaminD&TT Start Date*: 2013-03-05
    Sponsor Name:Medizinische Universität Graz, Innere Medizin
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men
    Medical condition: Male hypogonadism (total testosterone <3ng/ml)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10000193 Male sex hormone abnormalities HLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003585-14 Sponsor Protocol Number: D-US-60010-001 Start Date*: 2020-04-08
    Sponsor Name:Ipsen Bioscience, Inc.
    Full Title: An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not prev...
    Medical condition: Previously Untreated, Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) CZ (Completed) AT (Completed) FR (Completed) PT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003654-29 Sponsor Protocol Number: 1100.1486 Start Date*: 2007-11-08
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg B...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10020160 HIV disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PT (Completed) GB (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011800-44 Sponsor Protocol Number: DIM20 Start Date*: 2009-10-07
    Sponsor Name:Medivation, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease
    Medical condition: Huntington disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001866-15 Sponsor Protocol Number: 1182.71 Start Date*: 2007-07-12
    Sponsor Name:Boehringer Ingelheim France SAS
    Full Title: A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in three-clas...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Prematurely Ended) GR (Completed) PT (Prematurely Ended) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001888-23 Sponsor Protocol Number: TV7820-CNS-20002 Start Date*: 2014-03-25
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus...
    Medical condition: Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) AT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004083-21 Sponsor Protocol Number: E7438-G000-101 Start Date*: 2015-02-02
    Sponsor Name:Epizyme, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Advanced solid tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015811-42 Sponsor Protocol Number: GZGD03109 Start Date*: 2010-12-20
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients wit...
    Medical condition: Gaucher Disease Type I
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10018048 Gaucher's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001348-39 Sponsor Protocol Number: SEM-TAR-01-2014 Start Date*: 2014-12-03
    Sponsor Name:Fundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI)
    Full Title: A Phase II, randomized clinical trial to assess the impact of antiretroviral therapy over viral load in seminal fluid in antiretroviral-naive HIV-positive patients
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    17.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002271-97 Sponsor Protocol Number: F901318C21 Start Date*: 2017-04-07
    Sponsor Name:F2G Limited
    Full Title: An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of oral F901318 (combined with fluconazole and posaconazole) for antifungal prophylaxis in patients undergoing che...
    Medical condition: Invasive fungal disease in patients with acute myeloid leukemia under chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000304-16 Sponsor Protocol Number: B4Z-UT-S017 Start Date*: 2021-12-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder.
    Medical condition: Attention-Deficit/Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-010887-41 Sponsor Protocol Number: TMC125-TiDP2-C238 Start Date*: 2009-06-22
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combina...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 04:49:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA